Skip to main content
. 2022 Jan 28;14(3):679. doi: 10.3390/cancers14030679

Figure 1.

Figure 1

Personalized and molecular therapeutic strategies currently tested for non-WNT/non-SHH MB. RTKi = receptor tyrosine kinase inhibitor.